Lanean...
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
BACKGROUND: Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the...
Gorde:
| Argitaratua izan da: | J Immunother Cancer |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5168591/ https://ncbi.nlm.nih.gov/pubmed/28018599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0193-2 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|